clinical trial · NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·phase3·recruiting·n = 440
Relapsed or Refractory Multiple Myeloma (RRMM)BMS-986393CyclophosphamideFludarabineDaratumumabPomalidomideDexamethasoneCarfilzomib
brief summary
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
started
Mar 12, 2025
primary completion
Dec 30, 2027
completion
Jun 22, 2032
last updated
May 13, 2026
official title
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol